ERBB2 and lung cancer: In a similar manner, Ganetespib could also enhance the sensitivity of (1) radiotherapy in head and neck cancer cells[65], lung cancer[66]; (2) sorafenib in HepG2 cells[67]; (3) methotrexate in lung cancer A549 cells[68]; (4) lapatinib in refractory HER2-positive breast cancer[69]; (5) cyclophosphamide in hematological malignancies such as lymphomas[70]; (6) cytarabine in AML[71]; and (7) cisplatin in cervical cancer[72].